<DOC>
	<DOC>NCT02362672</DOC>
	<brief_summary>The purpose of this study is to determine whether a new opioid molecule, NKTR-181, is effective for the relief of moderate to severe chronic low back pain as compared to a placebo.</brief_summary>
	<brief_title>Efficacy and Safety Study of NKTR-181 in Opioid-Naive Subjects With Low Back Pain</brief_title>
	<detailed_description>This is an enriched enrollment, randomized withdrawal study with an open label, dose-titration period followed by a randomized, double-blind, placebo-control treatment of twelve weeks. During the double-blind treatment period, this study will evaluate the analgesic effect of NKTR-181 versus placebo in patients with moderate to severe chronic low back pain.</detailed_description>
	<mesh_term>Back Pain</mesh_term>
	<mesh_term>Chronic Pain</mesh_term>
	<mesh_term>Low Back Pain</mesh_term>
	<criteria>Male or nonpregnant, nonnursing female aged 18 to 75 years old Clinical diagnosis of moderate to severe, chronic nonneuropathic low back pain for at least six months Not experiencing adequate pain relief or have failed previous treatment with nonopioid analgesics Opioid analgesia is necessary Currently taking no more than 10 mg morphine sulfate equivalents per day of short acting opioids for 14 days prior to entry Females of child bearing potential must be using a highly effective form of birth control. All subjects must agree to use doublebarrier contraception during participation in this study and for at least 2 months after the last dose of the study drug. Willing and able to provide informed consent Taking extended release or longacting opioids within 6 months History of hypersensitivity, intolerance, or allergy to opioids Compression of spinal nerve root; spinal fracture, tumor, or abscess Surgical procedures on the low back in the last 12 months or facet nerve root block or radiofrequency ablation in the last 3 months Untreated moderate to severe sleep apnea</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>